Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929968 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00929968 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT00929968, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
Interventions
- DRUG Fluticasone
- BIOLOGICAL Placebo
- BIOLOGICAL VAK694
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00929968
The ClinicalTrials.gov registry entry for NCT00929968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluticasone is the first listed.
NCT00929968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00929968 about?
NCT00929968 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis". This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
What is the current status of trial NCT00929968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2009-06.
What interventions are being tested in trial NCT00929968?
The interventions under investigation include: Fluticasone (DRUG), Placebo (BIOLOGICAL), VAK694 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00929968?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.